Comparing Oral Vs. Vaginal Antifungal Treatment for Vulvovaginal Candidiasis

Article Sidebar

PDF
Published: Apr 24, 2024
DOI: https://doi.org/10.61919/jhrr.v4i2.836
Keywords:
Antifungal Therapy, Candidiasis Treatment, Fluconazole, Intravaginal Clotrimazole, Patient Compliance, Side Effects, Vulvovaginal Candidiasis, Women's Health, Treatment Efficacy

Main Article Content

Humeira Iqbal
Pulse Medical Complex Paragon City Lahore- Pakistan.
Afsah Laraib
University of Karachi- Pakistan.
Amima Asif Ghouri
Hamdard University Pakistan.
Fareeha Goher
University of Karachi- Pakistan.
Maryam Mehmood
University of Karachi- Pakistan.
Maheen Zahidi
University of Karachi- Pakistan.

Abstract

Background: Vulvovaginal candidiasis remains a pervasive gynecological concern, affecting a significant portion of women at least once in their lifetime. With the myriad of antifungal treatments available, the choice between oral and intravaginal therapies continues to challenge clinicians and patients alike, underscored by considerations of efficacy, side effects, and patient compliance.


Objective: This study aimed to compare the efficacy, side effects, and acceptability of oral fluconazole and intravaginal clotrimazole for treating vulvovaginal candidiasis in a population of married women aged 16 to 50 years.


Methods: Conducted as an interventional, experimental study at Pulse Medical Complex, Lahore, over six months from June 2023 to December 2023, 100 participants were randomly allocated to receive either a single dose of 150 mg oral fluconazole or 500 mg of clotrimazole administered as a vaginal pessary or 1% cream for three consecutive days. Data on demographic features, drug side effects, patient compliance, and cost-effectiveness were meticulously collected and analyzed using SPSS version 10.0.


Results: Fluconazole demonstrated a higher cure rate with 84% of patients symptom-free within an average of 5 days, compared to 86% for clotrimazole over an average of 8.5 days. Side effects were more common and varied with fluconazole, yet 96% of patients expressed a preference for this treatment due to its convenience and faster symptom resolution. Clotrimazole users reported a 74% preference rate, primarily due to cost considerations.


Conclusion: The study reaffirms the superior efficacy and patient acceptability of oral fluconazole over intravaginal clotrimazole for the treatment of uncomplicated vulvovaginal candidiasis, advocating for a patient-centered approach in the selection of antifungal therapy.

Article Details

How to Cite
Iqbal, H., Laraib, A., Ghouri , A. A., Goher , F., Mehmood , M., & Zahidi, M. (2024). Comparing Oral Vs. Vaginal Antifungal Treatment for Vulvovaginal Candidiasis. Journal of Health and Rehabilitation Research, 4(2), 276–281. https://doi.org/10.61919/jhrr.v4i2.836
Issue
Vol. 4 No. 2 (2024): 2024
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Humeira Iqbal, Pulse Medical Complex Paragon City Lahore- Pakistan.

MRCOG (UK), FCPS (Pakistan), FMAS (Germany), MBBS (KE), Consultant Obstetrics & Gynaecology, Pulse Medical Complex, Paragon City, Lahore- Pakistan.

Afsah Laraib, University of Karachi- Pakistan.

Executive, Quality Assurance Department, Martin Dow Marker Ltd., Research Institute of Pharmaceutical Sciences, University of Karachi- Pakistan.

Amima Asif Ghouri , Hamdard University Pakistan.

Lecturer in Pharmacognosy, Faculty of Pharmacy, Hamdard University, Research Institute of Pharmaceutical Sciences, University of Karachi- Pakistan.

Fareeha Goher , University of Karachi- Pakistan.

Executive, Research and Development Department, Herbion Pakistan Pvt. Ltd., Research Institute of Pharmaceutical Sciences, University of Karachi- Pakistan.

Maryam Mehmood , University of Karachi- Pakistan.

MPhil (Pharmacology), MPhil research, University of Karachi- Pakistan.

Maheen Zahidi, University of Karachi- Pakistan.

MPhil (Pharmacology), MPhil research, University of Karachi- Pakistan.

References

Wiliiam TA, Babila N, Kimbi HKJOJoO, Gynecology. Prevalence and Factors Associated with Trichomoniasis, Bacterial Vaginosis, and Candidiasis among Pregnant Women in a Regional Hospital in Cameroon. 2022;12(5):443-64.

Karaer A, Boylu M, Avsar AJEJoO, Gynecology, Biology R. Vaginitis in Turkish women: symptoms, epidemiologic–microbiologic association. 2005;121(2):211-5.

Frobenius W, Bogdan CJGuF. Diagnostic value of vaginal discharge, wet mount and vaginal pH–an update on the basics of gynecologic infectiology. 2015;75(04):355-66.

Pytka M, Kordowska-Wiater M, Jarocki PJPM-AoM. Microbiome of the women’s genital system. 2019;58(3):227-36.

Das S, Bhattacharjee MJ, Mukherjee AK, Khan MRJCRiM. Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics. 2023;49(2):256-82.

Sushma B. Microbiological Profile in Women with Symptomatic Vaginal Discharge: Rajiv Gandhi University of Health Sciences (India); 2020.

Ramya A. Occurrence of Bacterial Vaginosis, Vaginal Candidiasisand Vaginal Trichomoniasis in Patients Attending a Tertiary Carehospital: Rajiv Gandhi University of Health Sciences (India); 2017.

Multani HJAJoMS. Study of vulvovaginal candidiasis in symptomatic women of reproductive age group attending tertiary care institute, Haryana province. 2021;12(2).

Gupta RK, Stangaciu S. Apitherapy: holistic healing through the honeybee and bee products in countries with poor healthcare system. Beekeeping for poverty alleviation and livelihood security: Springer, Dordrecht; 2014. p. 413-46.

AHMAD A. M^ ttx of $ i) tlojQiop}| p in^ toteciinolosp: ALIGARH MUSLIM UNIVERSITY ALIGARH (INDIA; 2007.

Barker NM, Stovall TGJCG. General gynecology. 2015:253.

Maity S. To Evaluate the Efficacy of Amalaki Beeja Churna in the Management of Shwetapradara WSR to Leucorrhoea: Rajiv Gandhi University of Health Sciences (India); 2018.

EDITION FJO. Community Pharmacy Symptoms, Diagnosis And Treatment (4). pdf.53:4.

Kavitha A. Vulvar Disorders. Skin Diseases in Females: Springer; 2022. p. 391-412.

Scorzoni L, Fuchs BB, Junqueira JC, Mylonakis EJEoop. Current and promising pharmacotherapeutic options for candidiasis. 2021;22(7):887-8.

Nayak R, Kar B, Ghosh G, Rath GJIJoBM. Current trends in chitosan based nanopharmaceuticals for topical vaginal therapies. 2021;193:2140-52.

Bolla PK, Meraz CA, Rodriguez VA, Deaguero I, Singh M, Yellepeddi VK, et al. Clotrimazole loaded ufosomes for topical delivery: Formulation development and in-vitro studies. 2019;24(17):3139.

Denison HJ, Worswick J, Bond CM, Grimshaw JM, Mayhew A, Ramadoss SG, et al. Oral versus intra‐vaginal imidazole and triazole anti‐fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). 2020(8).

Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, et al. Biofilms and vulvovaginal candidiasis. 2019;174:110-25.

Abukhalil AD, Yousef M, Ammar M, Jaghama W, Al-Shami Nm, Naseef HA, et al. Practices, Efficacy, and Reported Side Effects Associated with Isotretinoin Treatment in Palestine. 2024:487-501.

Oori MJ, Mohammadi F, Norouzi-Tabrizi K, Fallahi-Khoshknab M, Ebadi AJAA. Prevalence of medication adherence in patients with hypertension in Iran: A systematic review and meta-analysis of studies published in 2000-2018. 2019;15(2):82.

Kumar N, Oles W, Howell BA, Janmohamed K, Lee ST, Funaro MC, et al. The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. 2021;127:108367.

Taudorf E, Jemec G, Hay R, Saunte DJJotEAoD, Venereology. Cutaneous candidiasis–an evidence‐based review of topical and systemic treatments to inform clinical practice. 2019;33(10):1863-73.

Deka S, Sharma S, Katakwar N, Kunte UJIJoR, Gynaecology Ri. Assessment of a Dazel-Kit (Fluconazole 150 mg, Azithromycin 1 gm, Secnidazole 1 g Two Tablets) for Syndromic Management of Abnormal Vaginal Discharge in Women of Kazakhstan. 2018;1(1):18-24.

Abdalla A, El-Sawy HS, Ramadan AAJERJ. Emergence of Advanced Antifungal-Delivery Approaches for the Treatment of Tinea Pedis. 2024.

Vuong NN, Hammond D, Kontoyiannis DPJJoF. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. 2023;9(4):464.

Aguilar Pérez KM. Development and characterization of essential oils based nanoliposomes with antifungal potentialities for biomedical applications. 2020.